Search research articles
Contact Us
Filters
Showing results (41-50 of 215) with videos related to
Page
of 22
Sort By:
British Journal of Haematology
|
December 6, 2019
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy
Daniel J Landsburg, Emily C Ayers, David A Bond, et al.
Leukemia
|
January 14, 2014
Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells
Y Zhong, D El-Gamal, J A Dubovsky, et al.
Haematologica
|
July 1, 2021
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Johannes Duell, Kami J Maddocks, Eva González-Barca, et al.
Haematologica
|
August 19, 2021
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Johannes Duell, Kami J. Maddocks, Eva González-Barca, et al.
Pediatric Blood & Cancer
|
March 22, 2025
Differences in Observed Outcomes and Toxicities for Adolescent and Young Adult Patients With Aggressive Mature B-Cell Lymphomas Treated at an Adult Versus Pediatric Cancer Center
Allison M LeHanka, Ann M Kebede, Neda Amirmokhtari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2020
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia
Kerry A Rogers, Ying Huang, Amy S Ruppert, et al.
The Journal of Clinical Investigation
|
July 18, 2017
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long, Kyle Beckwith, Priscilla Do, et al.
JAMA Oncology
|
July 17, 2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J Maddocks, Amy S Ruppert, Gerard Lozanski, et al.
Blood Advances
|
November 25, 2025
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma
Jia Ruan, David A Bond, Bijal D Shah, et al.
Leukemia & Lymphoma
|
October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin
Talha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
Page
of 22
Search research articles
Search
Showing results (41-50 of 215) with videos related to
Sort By:
Page
of 22
British Journal of Haematology
|
December 6, 2019
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy
Daniel J Landsburg, Emily C Ayers, David A Bond, et al.
Leukemia
|
January 14, 2014
Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells
Y Zhong, D El-Gamal, J A Dubovsky, et al.
Haematologica
|
July 1, 2021
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Johannes Duell, Kami J Maddocks, Eva González-Barca, et al.
Haematologica
|
August 19, 2021
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Johannes Duell, Kami J. Maddocks, Eva González-Barca, et al.
Pediatric Blood & Cancer
|
March 22, 2025
Differences in Observed Outcomes and Toxicities for Adolescent and Young Adult Patients With Aggressive Mature B-Cell Lymphomas Treated at an Adult Versus Pediatric Cancer Center
Allison M LeHanka, Ann M Kebede, Neda Amirmokhtari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2020
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia
Kerry A Rogers, Ying Huang, Amy S Ruppert, et al.
The Journal of Clinical Investigation
|
July 18, 2017
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long, Kyle Beckwith, Priscilla Do, et al.
JAMA Oncology
|
July 17, 2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J Maddocks, Amy S Ruppert, Gerard Lozanski, et al.
Blood Advances
|
November 25, 2025
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma
Jia Ruan, David A Bond, Bijal D Shah, et al.
Leukemia & Lymphoma
|
October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin
Talha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
Page
of 22